Calls
2
Kim Seon-ah
Senior Research Fellow, Hana Securities Research Center
Win Rate
50.0%
return
-0.7%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jul 20
$172400.00
+0.1%
Korean large-cap pharma/biotech companies like Celltrion, SK Biopharm, and Samsung Bioepis Holdings have the capital, BD capabilities, and R&D manpower to develop innovative first-in-class drugs. They are expected to produce novel therapies within about 3 years, matching China's rapid growth trajectory. These firms already have global tech-transfer track records and are building the ecosystem despite current stock underperformance.
Pharma & Biotech
Long
Jul 20
$78000.00
-1.5%
Korean large-cap pharma/biotech companies like Celltrion, SK Biopharm, and Samsung Bioepis Holdings have the capital, BD capabilities, and R&D manpower to develop innovative first-in-class drugs. They are expected to produce novel therapies within about 3 years, matching China's rapid growth trajectory. These firms already have global tech-transfer track records and are building the ecosystem despite current stock underperformance.
Pharma & Biotech
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Kim Seon-ah has 2 trade ideas tracked on Buzzberg across 2 tickers since July 2026. Most covered: 068270.KS, KOSDAQ 150 HEALTHCARE INDEX, SAMSUNG BIOEPIS HOLDINGS.
